persevERA trial: what clinicians have said so far
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
- NCT04546009 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep size, estimated: 301+ verified statements once built
Discussed at: 2026 ASCO Annual Meeting
We haven't built an HCP commentary report on persevERA (giredestrant plus palbociclib) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on persevERA so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 38 YouTube videos, typically up to 167 once built | |
| 35 posts on X, typically up to 154 once built | |
| 34 podcast episodes, typically up to 150 once built | |
| 1 video on X, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
- Interventions
- Giredestrant; Giredestrant-matched Placebo; Letrozole; Letrozole-matched Placebo; Palbociclib; LHRH Agonist
- Arms
- Giredestrant + Letrozole-matched Placebo + Palbociclib · Experimental
- Letrozole + Giredestrant-matched Placebo + Palbociclib · Active comparator
- Enrollment
- 992
- Primary outcomes
- Progression-Free Survival (PFS), as Determined by the Investigator According to RECIST v1.1
- Sponsor
- Hoffmann-La Roche
- Start
- Oct 9, 2020
- Primary completion
- Jan 30, 2026
- Results posted
- No
- Registry record
- NCT04546009 · updated Aug 17, 2026